- Home
- VSTM vs SWKH Comparison
VSTM vs SWKH Comparison
Compare VSTM & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- SWKH
- Stock Information
- Founded
- VSTM 2010
- SWKH 1996
- Country
- VSTM United States
- SWKH United States
- Employees
- VSTM N/A
- SWKH N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- SWKH Diversified Financial Services
- Sector
- VSTM Health Care
- SWKH Finance
- Exchange
- VSTM Nasdaq
- SWKH Nasdaq
- Market Cap
- VSTM 239.9M
- SWKH 201.5M
- IPO Year
- VSTM 2012
- SWKH 1999
- Fundamental
- Price
- VSTM $5.39
- SWKH $16.41
- Analyst Decision
- VSTM Strong Buy
- SWKH
- Analyst Count
- VSTM 8
- SWKH 0
- Target Price
- VSTM $12.43
- SWKH N/A
- AVG Volume (30 Days)
- VSTM 2.4M
- SWKH 8.6K
- Earning Date
- VSTM 03-13-2025
- SWKH 11-14-2024
- Dividend Yield
- VSTM N/A
- SWKH N/A
- EPS Growth
- VSTM N/A
- SWKH N/A
- EPS
- VSTM N/A
- SWKH 0.84
- Revenue
- VSTM $10,000,000.00
- SWKH $24,725,000.00
- Revenue This Year
- VSTM N/A
- SWKH N/A
- Revenue Next Year
- VSTM $117.91
- SWKH $6.17
- P/E Ratio
- VSTM N/A
- SWKH $19.71
- Revenue Growth
- VSTM N/A
- SWKH N/A
- 52 Week Low
- VSTM $2.10
- SWKH $15.14
- 52 Week High
- VSTM $14.22
- SWKH $18.49
- Technical
- Relative Strength Index (RSI)
- VSTM 53.22
- SWKH 53.85
- Support Level
- VSTM $5.08
- SWKH $16.25
- Resistance Level
- VSTM $6.02
- SWKH $16.64
- Average True Range (ATR)
- VSTM 0.68
- SWKH 0.35
- MACD
- VSTM -0.06
- SWKH 0.05
- Stochastic Oscillator
- VSTM 50.79
- SWKH 75.21
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About SWKH SWK Holdings Corporation
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.